What is the 13F Pro Quality Score for PRAX?

13F Pro ranks Praxis Precision Medicines, Inc. (PRAX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PRAX's current score at https://13fpro.ai/research/PRAX (free sign-up required for the full ranking).

Which hedge funds own the most PRAX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of PRAX include Orbis Allan Gray Ltd, BlackRock,, FMR. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/PRAX as soon as new 13F filings post.

Where does 13F Pro source PRAX data?

All Praxis Precision Medicines, Inc. fundamentals and ownership data come directly from SEC EDGAR. Praxis Precision Medicines, Inc. files with the SEC under CIK 1689548. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PRAX in?

Praxis Precision Medicines, Inc. (PRAX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is PRAX research updated on 13F Pro?

PRAX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Praxis Precision Medicines, Inc.(PRAX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1689548 PRAX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

PRAX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Praxis Precision Medicines, Inc. (PRAX), a Healthcare sector company. PRAX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Praxis Precision Medicines, Inc. reports net income of $-92.6M, free cash flow of $-86.2M. Top institutional holders of PRAX by reported 13-F value include Orbis Allan Gray Ltd, BlackRock,, FMR, based on the most recent SEC filings. PRAX trades on the Nasdaq exchange and files with the SEC under CIK 1689548. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PRAX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Praxis Precision Medicines, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-92.6M

Free Cash Flow

Q1 2026

$-86.2M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-100.0% YoY

$0.00FY 2025

FY22 $0.00FY23 $2.4MFY24 $8.6MFY25 $0.00

Net Income

-65.7% YoY

$-303.3MFY 2025

FY22 $-214.0MFY23 $-123.3MFY24 $-183.0MFY25 $-303.3M

Operating Income

-63.0% YoY

$-326.2MFY 2025

FY22 $-215.0MFY23 $-126.4MFY24 $-200.2MFY25 $-326.2M

EPS (Diluted)

-32.0% YoY

$-13.48FY 2025

FY22 $-69.65FY23 $-18.69FY24 $-10.21FY25 $-13.48

Total Assets

+94.1% YoY

$937.9MFY 2025

FY22 $115.1MFY23 $87.9MFY24 $483.1MFY25 $937.9M

Op. Cash Flow

-89.0% YoY

$-249.1MFY 2025

FY22 $-185.0MFY23 $-111.1MFY24 $-131.8MFY25 $-249.1M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$0.00 -100.0%	$8.6M +249.5%	$2.4M	$0.00	—	—
Net Income	$-303.3M -65.7%	$-183.0M -48.4%	$-123.3M +42.4%	$-214.0M -28.1%	$-167.1M -170.2%	$-61.8M
Operating Income	$-326.2M -63.0%	$-200.2M -58.4%	$-126.4M +41.2%	$-215.0M -28.5%	$-167.3M -170.0%	$-62.0M
EPS (Diluted)	$-13.48 -32.0%	$-10.21 +45.4%	$-18.69 +73.2%	$-69.65 -1667.8%	$-3.94 +49.9%	$-7.86
Total Assets	$937.9M +94.1%	$483.1M +449.3%	$87.9M -23.6%	$115.1M -60.7%	$292.7M -3.4%	$303.2M
Operating Cash Flow	$-249.1M -89.0%	$-131.8M -18.6%	$-111.1M +39.9%	$-185.0M -48.6%	$-124.6M -136.7%	$-52.6M

AI Insight: PRAX Financial Trends

PRAX remains pre-revenue with operating losses accelerating to -$106M in Q1 2026, though a large Q4 2025–Q1 2026 equity raise materially extends the cash runway.

• Operating losses have nearly tripled from -$37M in Q2 2024 to -$106M in Q1 2026, reflecting heavy clinical-stage spending.

• Operating cash outflows surged from -$27M in Q2 2024 to -$86M in Q1 2026, signaling accelerating cash consumption.

• Equity jumped from $344M in Q3 2025 to $1,410M in Q1 2026, indicating a substantial capital raise that bolsters the balance sheet.

• Revenue remains effectively $0M across seven of eight quarters; the lone $7M in Q4 2024 did not recur.

⚠ At -$86M quarterly cash burn, the $1,410M equity base provides roughly four years of runway — monitor burn acceleration closely.

⚠ Operating losses widened $29M quarter-over-quarter in Q4 2025 — steepest single-quarter deterioration in the dataset.

⚠ No debt reported across all periods; any future debt issuance would signal a meaningful shift in capital strategy.

AI Insight: PRAX Ratio Trends

Return metrics surged to deeply negative levels through Q3 2025 but have since recovered sharply, with ROIC improving from -91.2% to -30.0% by Q1 2026.

• ROIC deteriorated from -35.8% in Q2 2024 to a trough of -91.2% in Q3 2025, signaling accelerating cash burn through that period.

• ROIC rebounded meaningfully from -91.2% in Q3 2025 to -30.0% in Q1 2026, a 61pp improvement over two quarters.

• ROA followed the same pattern, troughing at -74.6% in Q3 2025 before recovering to -25.4% in Q1 2026.

⚠ OpMargin, NPM, and D/E are entirely absent across all periods, leaving capital structure and profitability context incomplete.

⚠ Despite the recent recovery, all return metrics remain deeply negative; the TTM ROIC of -25.3% confirms sustained cash consumption.

Get alerted when PRAX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Praxis Precision Medicines, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PRAX

Orbis Allan Gray Ltd
$796.6M2,472,480 sh
BlackRock, Inc.
$749.1M2,324,929 sh
FMR LLC
$696.2M2,160,943 sh
PERCEPTIVE ADVISORS LLC
$656.0M2,035,986 sh
BAKER BROS. ADVISORS LP
$564.9M1,753,198 sh
VANGUARD CAPITAL MANAGEMENT LLC
$393.7M1,221,944 sh
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$310.4M963,351 sh
DRIEHAUS CAPITAL MANAGEMENT LLC
$305.8M949,225 sh
Cormorant Asset Management, LP
$285.3M885,500 sh
STATE STREET CORP
$284.9M884,238 sh

Fund	Value	Shares
Orbis Allan Gray Ltd	$796.6M	2,472,480
BlackRock, Inc.	$749.1M	2,324,929
FMR LLC	$696.2M	2,160,943
PERCEPTIVE ADVISORS LLC	$656.0M	2,035,986
BAKER BROS. ADVISORS LP	$564.9M	1,753,198
VANGUARD CAPITAL MANAGEMENT LLC	$393.7M	1,221,944
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	$310.4M	963,351
DRIEHAUS CAPITAL MANAGEMENT LLC	$305.8M	949,225
Cormorant Asset Management, LP	$285.3M	885,500
STATE STREET CORP	$284.9M	884,238

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PRAX on your watchlist

Track score changes the day Praxis Precision Medicines, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PRAX a good stock to buy?

13F Pro's AI-powered analysis of Praxis Precision Medicines, Inc. (PRAX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PRAX are available on the PRAX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own PRAX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PRAX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Praxis Precision Medicines, Inc.'s investment landscape.